Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre
World Journal of Gastroenterology · 28.08.2026 · 32 (32)
DOI: 10.3748/wjg.118570 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastroenterology, online erschienen am 28.08.2026. Verfasst von Su Chen Fong und 8 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Stereotactic body radiotherapy (SBRT) has emerged as a promising treatment modality for hepatocellular carcinoma (HCC), offering precise high-dose radiation delivery while preserving liver function. However, real-world prospective data from transplant centres, particularly regarding bridging and salvage applications, remain limited. We hypothesised that SBRT would achieve durable local control with acceptable toxicity across diverse clinical indications in a real-world tertiary transplant-centre cohort. AIM To evaluate efficacy and safety of SBRT for HCC in a prospective cohort at a tertiary transplant centre. METHODS We conducted a prospective, single-centre registry of consecutive HCC patients treated with SBRT between August 2016 and June 2022. The primary endpoint was local control. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and treatment-related toxicity. RESULTS With a median follow-up of 23.6 months, 58 patients received 60 SBRT courses for 64 HCC lesions. Most were male (81%), cirrhotic (93.1%) and Child-Pugh A disease (74.1%). Barcelona Clinic Liver Cancer stages were 0/A in 43%, B in 40%, and C in 17%. Most patients (90%) had received prior locoregional treatment. The median prescribed biologically effective dose was 72 Gy, most commonly 40 Gy in 5 fractions. One- and two-year local control rates were 90% and 85%, OS 80% and 60%, and PFS 55% and 40%, respectively. Isolated local failure occurred in 13.3%, while intrahepatic and extrahepatic progression occurred in 35% and 13%. Treatment completion was 98%, with no grade ≥ 3 toxicities. CONCLUSION SBRT achieved durable local control with minimal toxicity for HCC, supporting its role as an effective liver-directed treatment option across curative, bridging and salvage clinical settings.
Zitieren
APA
Fong, S. C., Ng, S. P., Italiano, D., Chung, W., Vaz, K., Fink, M., Goodwin, M., Ranatunga, D., & Khor, R. (2026). Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre. World Journal of Gastroenterology, 32(32). https://doi.org/10.3748/wjg.118570
Vancouver
Fong SC, Ng SP, Italiano D, Chung W, Vaz K, Fink M, et al. Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre. World Journal of Gastroenterology. 2026;32(32). doi:10.3748/wjg.118570
BibTeX
@article{Fong2026,
author = {Fong, Su Chen and Ng, Sweet Ping and Italiano, Dominic and Chung, William and Vaz, Karl and Fink, Michael and Goodwin, Mark and Ranatunga, Dinesh and Khor, Richard},
title = {Stereotactic body radiotherapy for hepatocellular carcinoma: Five-year prospective registry outcomes from an Australian tertiary transplant centre},
journal = {World Journal of Gastroenterology},
year = {2026},
volume = {32},
number = {32},
doi = {10.3748/wjg.118570}
}
EUVIMED